Quarterly report · Q2
4626.TEDINET S100PGNK
Period2022-04-01 → 2022-09-30
Filed2022-11-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥52.8bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥98.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥48.3bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥10.5bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥9.3bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥10.2bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥18.1bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥9.5bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥10.2bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥9.5bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥7.5bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥11.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥6.7bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥7.5bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥6.8bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥198.4bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥189.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥184.0bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥105.0bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥103.8bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥93.4bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥85.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥81.5bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥57.3bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥51.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥57.2bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥51.2bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥51.6bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥54.3bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥12.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥18.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥8.5bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥11.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥6.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥2.9bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥11.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥133.32 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.86 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥209.13 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.84 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥63.83 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 47.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 45.2% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 44.1% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥1.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥1.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥142m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | ¥30m |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥38.7bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥38.7bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥10.4bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥12.4bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥12.4bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.0bn |
| —segment total | revenue | 2022-04-01 → 2022-09-30 | ¥51.1bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥51.1bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥11.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥52.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥52.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥142m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥11.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥1.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥54m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | ¥6m |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥34.9bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥34.9bn |
| jpcrp040300-q2r_E00913-000Electronics Materialsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥8.3bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥11.8bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥11.8bn |
| jpcrp040300-q2r_E00913-000Medical And Pharmaceuticalsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.5bn |
| —segment total | revenue | 2021-04-01 → 2021-09-30 | ¥46.6bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥46.6bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥9.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥48.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥48.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥54m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥9.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 506
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -4260000000 | JPY |
| Purchase of intangible assets inv cf | Prior1YTDDuration | -546000000 | JPY |
| Purchase of intangible assets inv cf | CurrentYTDDuration | -285000000 | JPY |
| Purchase of investment securities inv cf | Prior1YTDDuration | -262000000 | JPY |
| Purchase of investment securities inv cf | CurrentYTDDuration | -301000000 | JPY |
| Other net inv cf | Prior1YTDDuration | -17000000 | JPY |
| Other net inv cf | CurrentYTDDuration | 12000000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -6677000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -4456000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | 1360000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | -1933000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YTDDuration | 1500000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYTDDuration | 7000000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -4817000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -5308000000 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -0 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -628000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -2695000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -2085000000 | JPY |
| Dividends paid to non controlling interests fin cf | Prior1YTDDuration | -68000000 | JPY |
| Dividends paid to non controlling interests fin cf | CurrentYTDDuration | － | JPY |
| Proceeds from issuance of common stock fin cf | Prior1YTDDuration | 142000000 | JPY |
| Proceeds from issuance of common stock fin cf | CurrentYTDDuration | 177000000 | JPY |
| Other net fin cf | Prior1YTDDuration | -114000000 | JPY |
| Other net fin cf | CurrentYTDDuration | -150000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -4693000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -2929000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 105000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 863000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -2737000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 6077000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 54309000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 51152000000 | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | Prior1YTDDuration | － | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | CurrentYTDDuration | 15000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 51572000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 57245000000 | JPY |
| Trade notes receivable transferred by endorsement | Prior1YearInstant | 604000000 | JPY |
| Trade notes receivable transferred by endorsement | CurrentQuarterInstant | 714000000 | JPY |
| Salaries sga | Prior1YTDDuration | 1937000000 | JPY |
| Salaries sga | CurrentYTDDuration | 2074000000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 464000000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 495000000 | JPY |
| Provision for directors bonuses sga | Prior1YTDDuration | 283000000 | JPY |
| Provision for directors bonuses sga | CurrentYTDDuration | 327000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 120000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 116000000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | -21000000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | -17000000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 1625000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |